STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4149 by analyst upside · 2026-06-27
CLOV
Clover Health Investments, Corp.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
-23.3%
implied upside to consensus target
Current Price $5.41
Consensus Target $4.15
Bull Target $4.75
Bear Target $3.5
Analysts Covering 3
ANALYST CONSENSUS — HOLD
Strong Buy
0
Buy
1
Hold
2
Sell
0
52-Week Low $1.58
52-Week High $5.49
YTD Return +124.5%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E 54.1x
EPS (TTM) $-0.12
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $2.2B
Profit Margin -2.6%
52-WEEK RANGE
52-Week Low $1.58
52-Week High $5.49
Current Price $5.41
Bear Target $3.5
Bull Target $4.75
● Now $5.41 ● Target $4.15
TRADING DATA
Avg Volume 7.5M
YTD Return +124.5%
Analyst Count 3
Consensus Hold
Upside to Target -23.3%
Last Updated 2026-06-27

ANALYST SUMMARY

Clover Health Investments, Corp. (CLOV) is currently trading at $5.41 with a Wall Street consensus price target of $4.15, which is 23.3% below the current price over the next 12 months. 3 analysts currently cover CLOV, with a consensus rating of Hold — 33% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $4.75, while the most cautious has a target of $3.5.

CLOV operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 124.5% year-to-date and is currently trading near the upper end of its 52-week range of $1.58 – $5.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CLOV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS — Reiterated
Neutral → Neutral 2026-06-11 33% win rate (6 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-06-04 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-03-20 Building track record
Leerink Partners — Reiterated
Market Perform → Market Perform 2026-03-05 29% win rate (7 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-01-20 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2025-11-06 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2025-08-07 Building track record
UBS — Reiterated
Neutral → Neutral 2025-08-06 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →